We are excited to announce that Lemna Bio, a standout company from the DayOne Accelerator 2025 cohort, is the first startup selected to join DayOne NEXT, our long-term support program for the most promising DayOne founders. 

DayOne NEXT reflects a simple belief: the journey doesn’t end with the accelerator – it’s just the beginning. Designed as a hands-on, long-term venture builder, the program supports a small number of exceptional startups as they build, scale and anchor their R&D in the Basel Area. Participants receive a non-dilutive CHF 50,000 grant, up to 12 months of tailored operational and strategic support (valued at up to CHF 50,000), workspace at the Switzerland Innovation Park Basel Area, and deep integration into the region’s world-leading life sciences ecosystem.  

By working side-by-side with founders, DayOne NEXT provides not just resources, but sustained, highly personalized support – from fractional expertise and mentorship to ecosystem access and visibility opportunities – helping startups transition from early traction to long-term impact.  

Lemna Bio is a techbio company building a structural AI platform to decode and validate hard intracellular targets. While advances in chemistry are unlocking new ways to engage biological targets, failures in drug discovery are still largely driven by incorrect target selection or an incomplete understanding of how to engage them in a disease context. Lemna Bio develops the tools, intelligence and experimental data to help drug discovery teams de-risk target biology and disease mechanisms early – before committing to costly chemistry efforts. 

Commenting on the milestone, Moustafa Houmani, Co-founder & CEO of Lemna Bio, said, “DayOne provided us with rare, first-hand insights into how pharmaceutical companies operate – insights that typically take years to acquire. Being selected for DayOne NEXT is an exciting opportunity to continue building with the right support and ecosystem around us.”  

With Lemna Bio as the first company in DayOne NEXT, we are proud to deepen our commitment to the most promising founders in our community and to support them as they scale breakthrough innovations at the intersection of technology and pharma R&D. 

The journey doesn’t end with the accelerator – in many ways, it’s just the beginning. 

We are proud to announce the launch of DayOne NEXT, a long-term support program designed to help the most promising startups from the DayOne accelerator cohort build, scale and anchor their R&D in the Basel Area. It is a hands-on, non-profit venture builder for exceptional early-stage teams, where we provide capital (no equity, no fees), workspace and deeply embedded operational support – and we stay for the long term. 

Each year, up to three startups from the accelerator cohort will be selected to join DayOne NEXT and receive tailored, long-term backing to transform breakthrough science and technology into real-world impact. 

DayOne NEXT is designed around a simple idea: early-stage healthtech, techbio and pharma-enabling ventures need more than short-term momentum. They need time, focus, ecosystem integration and highly tailored support. We will work side-by-side with a small number of exceptional founders and actively help build the company.

What this means in practice…

For the startups we back, this isn’t just “access to benefits.” It’s real involvement. We embed ourselves within the team – working on strategy, fundraising, hiring, positioning and whatever is mission-critical. 

The program is intentionally selective. We select top ventures from the DayOne accelerator program with strong scientific foundations and a robust intellectual property position – or a clear path to defensibility. Companies should have an active R&D component, require technical, regulatory or clinical support beyond business development, and have raised limited external funding so that the grant delivers meaningful impact.

We also prioritize engaged, collaborative teams with a clear strategic rationale for locating R&D in the Basel Area and strong alignment with the region’s ecosystem.  

We deliberately work with very few startups so we can go deep. This is high-conviction, long-term venture building. 

DayOne NEXT represents a new chapter in our mission: not just to accelerate innovation, but to anchor it, nurture it and help it scale sustainably within the Basel ecosystem.

It is more than just follow-on funding. It is a long-term partnership – aligning capital, expertise and ecosystem access to help exceptional founders build enduring, globally impactful health innovation. 

Learn more about the DayOne accelerator program here.